RECRUITING

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Description

This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24 and 2024/25 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.

Conditions

InfluenzaCommunity-acquired PneumoniaCardiovascular Events
Talk to us

Related Conditions:

InfluenzaCommunity-acquired PneumoniaCardiovascular Events

Study Overview

On this page

Study Details

Study overview

This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24 and 2024/25 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.

Relative Vaccine Effectiveness of Adjuvanted Quadrivalent Inactivated Influenza Vaccine vs High-Dose Quadrivalent Inactivated Influenza Vaccine Among Adults ≥65 Years for the 2023-24 and 2024-25 Seasons

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Condition
Influenza
Intervention / Treatment

-

Contacts and Locations

Oakland

Kaiser Permanente Northern California (entire region), Oakland, California, United States, 94612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥65 years at the time of influenza vaccination
  • * KPNC member at the time of vaccination
  • * Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons
  • * Age \<65 years at the time of influenza vaccination
  • * Received either aIIV4 or HD-IIV4 in the inpatient setting
  • * Receive more than one influenza vaccination during a single season period (i.e., 2023/24 or 2024/25 influenza seasons)
  • * Receive an influenza vaccination outside of KPNC

Ages Eligible for Study

65 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Kaiser Permanente,

Study Record Dates

2026-05